ONCAlert | 2018 ASCO Annual Meeting

A Study Examining Brentuximab Vedotin in Patients With High-Risk Large B-Cell Lymphoma

Kathryn Kolibaba, MD
Published Online: 1:00 AM, Tue December 6, 2016

Kathryn Kolibaba, MD, associate chair of hematology research program, US Oncology, discusses an ongoing phase 2 study of brentuximab vedotin (Adcetris) with as frontline therapy in patients with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).
 

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.